Antibody ID	ANTI0MGGCU
Antibody Name	CD74 Milatuzumab DANAPAE152C S375C
Synonyms	CD74 Milatuzumab DANAPAE152C S375C    Click to Show/Hide
Antigen Name	HLA class II histocompatibility antigen gamma chain (CD74)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.03 nM	High CD74 expression (CD74 +++)
Method Description	CD74 Milatuzumab DANAPAE152C S375C-P1-L12-P4 was tested in EOL-1
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.118 nM	High CD74 expression (CD74 +++)
Method Description	CD74 Milatuzumab DANAPAE152C S375C-P1-L18-P2 was tested in EOL-1
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.122 nM	High CD74 expression (CD74 +++)
Method Description	CD74 Milatuzumab DANAPAE152C S375C-P1-L17-P2 was tested in EOL-1
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.217 nM	High CD74 expression (CD74 +++)
Method Description	CD74 Milatuzumab DANAPAE152C S375C-P2-L13-P1 was tested in EOL-1
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.238 nM	High CD74 expression (CD74 +++)
Method Description	CD74 Milatuzumab DANAPAE152C S375C-P1-L30-P2 was tested in EOL-1
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.247 nM	High CD74 expression (CD74 +++)
Method Description	CD74 Milatuzumab DANAPAE152C S375C-P1-L32-P2 was tested in EOL-1
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.269 nM	High CD74 expression (CD74 +++)
Method Description	CD74 Milatuzumab DANAPAE152C S375C-P1-L27-P1 was tested in EOL-1
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.292 nM	High CD74 expression (CD74 +++)
Method Description	CD74 Milatuzumab DANAPAE152C S375C-P1-L12-P3 was tested in EOL-1
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.42 nM	High CD74 expression (CD74 +++)
Method Description	CD74 Milatuzumab DANAPAE152C S375C-P1-L11-P1 was tested in EOL-1
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	0.853 nM	High CD74 expression (CD74 +++)
Method Description	CD74 Milatuzumab DANAPAE152C S375C-P1-L35-P1 was tested in EOL-1
In Vitro Model	Chronic eosinophilic leukemia	EoL-1 cells		CVCL_0258

Ref 1	Antibody-drug conjugates of antineoplastic compounds and methods of use thereof